393 related articles for article (PubMed ID: 33936058)
1. Clinical Experience and Recent Advances in the Development of
Oladejo M; Paterson Y; Wood LM
Front Immunol; 2021; 12():642316. PubMed ID: 33936058
[TBL] [Abstract][Full Text] [Related]
2. Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.
Wood LM; Paterson Y
Front Cell Infect Microbiol; 2014; 4():51. PubMed ID: 24860789
[TBL] [Abstract][Full Text] [Related]
3. Prospects and progress of Listeria-based cancer vaccines.
Bolhassani A; Naderi N; Soleymani S
Expert Opin Biol Ther; 2017 Nov; 17(11):1389-1400. PubMed ID: 28823183
[TBL] [Abstract][Full Text] [Related]
4. Promises and challenges for the development of Listeria monocytogenes-based immunotherapies.
Brockstedt DG; Dubensky TW
Expert Rev Vaccines; 2008 Sep; 7(7):1069-84. PubMed ID: 18767955
[TBL] [Abstract][Full Text] [Related]
5. Clinical development of Listeria monocytogenes-based immunotherapies.
Le DT; Dubenksy TW; Brockstedt DG
Semin Oncol; 2012 Jun; 39(3):311-22. PubMed ID: 22595054
[TBL] [Abstract][Full Text] [Related]
6.
Ding YD; Shu LZ; He RS; Chen KY; Deng YJ; Zhou ZB; Xiong Y; Deng H
Front Immunol; 2023; 14():1278011. PubMed ID: 37868979
[TBL] [Abstract][Full Text] [Related]
7. Listeria monocytogenes and its products as agents for cancer immunotherapy.
Guirnalda P; Wood L; Paterson Y
Adv Immunol; 2012; 113():81-118. PubMed ID: 22244580
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic.
Singh R; Wallecha A
Hum Vaccin; 2011 May; 7(5):497-505. PubMed ID: 21422819
[TBL] [Abstract][Full Text] [Related]
9. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
[TBL] [Abstract][Full Text] [Related]
10. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action.
Kim SH; Castro F; Paterson Y; Gravekamp C
Cancer Res; 2009 Jul; 69(14):5860-6. PubMed ID: 19584282
[TBL] [Abstract][Full Text] [Related]
11. Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy.
Singh R; Paterson Y
Expert Rev Vaccines; 2006 Aug; 5(4):541-52. PubMed ID: 16989634
[TBL] [Abstract][Full Text] [Related]
12. [Listeria monocytogenes: a dangerous pathogen used as a vector for the new generation of vaccines].
Tkachuk MV; Iarovinskiĭ FO; Tonevitskiĭ AG
Vopr Med Khim; 2000; 46(3):256-64. PubMed ID: 11033885
[TBL] [Abstract][Full Text] [Related]
13. Harnessing Listeria monocytogenes to target tumors.
Gravekamp C; Paterson Y
Cancer Biol Ther; 2010 Feb; 9(4):257-65. PubMed ID: 20139702
[TBL] [Abstract][Full Text] [Related]
14. Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease.
Weiskirch LM; Paterson Y
Immunol Rev; 1997 Aug; 158():159-69. PubMed ID: 9314084
[TBL] [Abstract][Full Text] [Related]
15. Live-attenuated Listeria-based immunotherapy.
Rothman J; Paterson Y
Expert Rev Vaccines; 2013 May; 12(5):493-504. PubMed ID: 23659298
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
[TBL] [Abstract][Full Text] [Related]
17. T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C.
Flickinger JC; Singh J; Yarman Y; Carlson RD; Barton JR; Waldman SA; Snook AE
Front Immunol; 2022; 13():855759. PubMed ID: 35355987
[TBL] [Abstract][Full Text] [Related]
18. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
19. Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy.
Wallecha A; Maciag PC; Rivera S; Paterson Y; Shahabi V
Clin Vaccine Immunol; 2009 Jan; 16(1):96-103. PubMed ID: 19020110
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors.
Wood LM; Guirnalda PD; Seavey MM; Paterson Y
Immunol Res; 2008; 42(1-3):233-45. PubMed ID: 19018479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
